CN108042489A - A kind of dronedarone hydrochloride self-micro emulsion formulation and preparation method thereof - Google Patents
A kind of dronedarone hydrochloride self-micro emulsion formulation and preparation method thereof Download PDFInfo
- Publication number
- CN108042489A CN108042489A CN201711378959.9A CN201711378959A CN108042489A CN 108042489 A CN108042489 A CN 108042489A CN 201711378959 A CN201711378959 A CN 201711378959A CN 108042489 A CN108042489 A CN 108042489A
- Authority
- CN
- China
- Prior art keywords
- micro emulsion
- self
- emulsion formulation
- dronedarone hydrochloride
- emulsifier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a kind of dronedarone hydrochloride self-micro emulsion formulations and preparation method thereof, it is that dronedarone hydrochloride, oil phase, emulsifier, assistant for emulsifying agent are formed liquid self-micro emulsion formulation or gained liquid self-micro emulsion formulation is further made Solid Self-microemulsion preparation with excipient.
Description
Technical field
The invention belongs to pharmaceutical technology fields, and in particular to a kind of dronedarone hydrochloride self-micro emulsion formulation and its preparation side
Method.
Background technology
Dronedarone（Dronedarone）It is a kind of new antiarrhythmic drug, it is by French mono- An Wante of Sai Nuofei
Company develops, and is registered in USA and EU, China is approved clinic in July, 2006.Arrhythmia cordis often perplex many patients and
The clinical practice of doctor, particularly amiodarone, because its control to many Premature Ventricular Beats, auricular fibrillation or auricular flutter
It makes and receives the effect of fine, but long-term larger amount of application, make its side effect cause blemish in an otherwise perfect thing, particularly it causes
Liver, lung, thyroid gland and cornea etc..The medical instrument has and amiodarone（amiodarone）Similar electro physiology effect, is the latter's
More novel drugs are substituted, because it is free of iodine.Therefore it will not cause and the relevant adverse reaction of iodine.Multaq is a kind of anti-arrhythmia cordis
Drug trembles the risk being hospitalized with atrial flutter patients by cardiovascular disease for reducing generation is sudden with permanent atrial, these
Patient occurred auricular fibrillation or auricular flutter and had cardiovascular risk factors in the recent period.Research data shows that dronedarone exists
Control atrial fibrillation room is flutterred in terms of breaking-out like very promising, because it improves the side effect of amiodarone it is kept to have to arrhythmia cordis
There is a new product of good therapeutic effect.Separately there is document report：Dronedarone reduces atrial fibrillation patients cardiovascular event or death
The incidence that source property is hospitalized.Dronedarone can reduce patient's cardiovascular disease for first proof and be hospitalized the auricular fibrillation drug of risk,
Auricular flutter can develop into auricular fibrillation.
The content of the invention
It is an object of the invention to provide a kind of dronedarone hydrochloride self-micro emulsion formulations and preparation method thereof, can significantly carry
High dronedarone hydrochloride dissolution in vitro and vivo biodistribution utilization rate, and raw material is easy to get, preparation process simple possible, yield height,
It is at low cost, it can realize industrialization large-scale production, there is significant economic benefit.
To achieve the above object, the present invention adopts the following technical scheme that：
A kind of dronedarone hydrochloride self-micro emulsion formulation is specially a kind of liquid self-micro emulsion formulation or a kind of Solid Self-microemulsion system
Agent.
The liquid self-micro emulsion formulation is made of dronedarone hydrochloride, oil phase, emulsifier, assistant for emulsifying agent；Its each original used
Expect that percentage is：Dronedarone hydrochloride 1% ~ 10%, oil phase 5% ~ 80%, emulsifier 5% ~ 60%, assistant for emulsifying agent 5% ~ 60%,
The sum of each raw material weight percentage is 100%；
Wherein, the oil phase is Sunsoft 8090, oleic acid LABRAFIL M 1944CS, ethyl oleate, caprylic capric triglycerin
One or more of ester, oleic acid；
The emulsifier is Labraso, Tween-80, Solutol HS15, polyoxy second
One or more of 35 castor oil of alkene, -40 rilanit special of polyethylene glycol；
The assistant for emulsifying agent is one or more of diethylene glycol monoethyl ether, propylene glycol, polyethylene glycol 400, glycerine.
The preparation method of the liquid self-micro emulsion formulation is that dronedarone hydrochloride is added to oil phase, emulsifier or helps emulsification
In agent dissolve after, add other raw materials and be uniformly mixed, using conventional method it is filling in soft capsule to obtain the final product.
The Solid Self-microemulsion preparation be the liquid that will be made of dronedarone hydrochloride, oil phase, emulsifier, assistant for emulsifying agent from
Microemulsion formulation is further made with excipient；The weight ratio of liquid self-micro emulsion formulation and excipient used is 1:1~1:60；
Wherein, the excipient is microcrystalline cellulose, lactose, PVP K30, one kind in silica or several
Kind.
The preparation method of the Solid Self-microemulsion preparation is that dronedarone hydrochloride is added to oil phase, emulsifier or helps emulsification
After being dissolved in agent, other raw materials that addition prepares needed for liquid self-micro emulsion formulation are uniformly mixed, then by liquid obtained from micro emulsion
Preparation is uniformly mixed with excipient, and piece agent is prepared using direct powder compression；Or use dry granulation or wet granulation work
Skill mixes it with other auxiliary materials, tabletting prepares piece agent；Or pellet is prepared by extrusion spheronization method, centrifugal granulation, it fills
Enter in hard shell capsules；
Other described auxiliary materials include disintegrant, adhesive, lubricant.
The remarkable advantage of the present invention is：Self-micro emulsifying medicament delivery system can make dronedarone hydrochloride in preparation and intestinal fluid
Dissolved state is kept, and the micro emulsion drop formed after self-emulsifying has minimum grain size, ensure that larger dispersion degree, it can be notable
Improve solubility and dissolution rate of the dronedarone hydrochloride in gastro-intestinal Fluid；Lipid excipient in prescription can promote chylomicron point
It secretes, and then promotes dronedarone hydrochloride through lymphatic transport.
Dronedarone hydrochloride is prepared into self-micro emulsion formulation and can reach raising dissolution in vitro and vivo biodistribution profit by the present invention
With the effect of rate, and raw material is easy to get needed for preparation, preparation process simple possible, and yield is high, at low cost, can realize that industrialization is big
Large-scale production has significant economic benefit.
Specific embodiment
In order to which content of the present invention is made to easily facilitate understanding, With reference to embodiment to of the present invention
Technical solution is described further, but the present invention is not limited only to this.
Embodiment 1：The preparation of dronedarone hydrochloride self-microemulsion soft capsules
| Dronedarone hydrochloride | 1g |
| Sunsoft 8090 | 100g |
| Labraso | 50g |
| Diethylene glycol monoethyl ether | 50g |
Preparation process：
Dronedarone hydrochloride is added in Sunsoft 8090 and is stirred to dissolve, sequentially adds caprylic capric polyethylene glycol
Glyceride, diethylene glycol monoethyl ether, stirring make it after mixing, it is filling in soft capsule to obtain the final product.
Embodiment 2：The preparation of dronedarone hydrochloride self-microemulsion soft capsules
| Dronedarone hydrochloride | 1g |
| Oleic acid LABRAFIL M 1944CS | 100g |
| Ethyl oleate | 50g |
| Tween-80 | 25g |
| Propylene glycol | 25g |
Preparation process：
Dronedarone hydrochloride is added in oleic acid LABRAFIL M 1944CS and is stirred to dissolve, ethyl oleate is sequentially added, spits
Temperature -80, propylene glycol, stirring make it after mixing, it is filling in soft capsule to obtain the final product.
Embodiment 3：The preparation of dronedarone hydrochloride self-microemulsion soft capsules
| Dronedarone hydrochloride | 1g |
| Solutol HS15 | 75g |
| Sad certain herbaceous plants with big flowers acid glyceryl ester | 50g |
| Oleic acid | 25g |
| Emulsifier EL-35 | 25g |
| Polyethylene glycol 400 | 25g |
Preparation process：
Dronedarone hydrochloride is added in Solutol HS15 and is stirred to dissolve, sequentially adds sad certain herbaceous plants with big flowers
Sour glyceryl ester, oleic acid, Emulsifier EL-35, polyethylene glycol 400, stirring makes it after mixing, filling in soft capsule
In to obtain the final product.
Embodiment 4：The preparation of dronedarone hydrochloride Solid Self-microemulsion piece
| Dronedarone hydrochloride | 5g |
| Diethylene glycol monoethyl ether | 75g |
| Sunsoft 8090 | 10g |
| Sad certain herbaceous plants with big flowers acid polyethylene glycol glyceride | 15g |
| Microcrystalline cellulose | 85g |
| Sodium carboxymethyl starch | 15g |
Preparation process：
Dronedarone hydrochloride is added in diethylene glycol monoethyl ether and is stirred to dissolve, sequentially adds linoleic acid list glycerine
Ester, sad certain herbaceous plants with big flowers acid polyethylene glycol glyceride, stirring make it after mixing, add in microcrystalline cellulose, sodium carboxymethyl starch, wet method
Pelletizing press sheet to get.
Embodiment 5：The preparation of dronedarone hydrochloride Solid Self-microemulsion piece
| Dronedarone hydrochloride | 4g |
| Oleic acid LABRAFIL M 1944CS | 35g |
| Ethyl oleate | 10g |
| Tween-80 | 15g |
| Propylene glycol | 15g |
| Lactose | 95g |
| Crosslinked polyvinylpyrrolidone | 15g |
| Magnesium stearate | 5g |
Preparation process：
After oleic acid LABRAFIL M 1944CS, ethyl oleate mixing, dronedarone hydrochloride is added thereto and is stirred to dissolve, then according to
Secondary addition Tween-80, propylene glycol, stirring make it after mixing, add in lactose, crosslinked polyvinylpyrrolidone, dry granulation
Afterwards, add in magnesium stearate tabletting to get.
Embodiment 6：The preparation of dronedarone hydrochloride Solid Self-microemulsion piece
| Dronedarone hydrochloride | 8g |
| Caprylic capric glyceryl ester | 35g |
| Oleic acid | 10g |
| Solutol HS15 | 15g |
| - 40 rilanit special of polyethylene glycol | 15g |
| Lactose | 95g |
| Crosslinked polyvinylpyrrolidone | 15g |
| Silica | 5g |
Preparation process：
After caprylic capric glyceryl ester, oleic acid mixing, dronedarone hydrochloride is added thereto and is stirred to dissolve, is sequentially added
Solutol HS15, -40 rilanit special of polyethylene glycol, stirring make it after mixing, add in lactose, hand over
Join polyvinylpyrrolidone, silica, direct powder compression to get.
Embodiment 7：The preparation of dronedarone hydrochloride Solid Self-microemulsion micro pill capsule
| Dronedarone hydrochloride | 10g |
| Diethylene glycol monoethyl ether | 70g |
| Sunsoft 8090 | 5g |
| Labraso | 5g |
| Microcrystalline cellulose | 75g |
| Lactose | 25g |
| Sodium carboxymethyl starch | 10g |
Preparation process：
Dronedarone hydrochloride is added in diethylene glycol monoethyl ether and is stirred to dissolve, sequentially adds linoleic acid list glycerine
Ester, Labraso, stirring make it after mixing, add in microcrystalline cellulose, lactose, carboxymethyl starch
Sodium, mixing, extrusion spheronization method are prepared into pellet, it is encapsulated to obtain the final product.
Embodiment 8：The preparation of dronedarone hydrochloride Solid Self-microemulsion micro pill capsule
| Dronedarone hydrochloride | 2g |
| Oleic acid LABRAFIL M 1944CS | 50g |
| Ethyl oleate | 25g |
| Tween-80 | 5g |
| Propylene glycol | 5g |
| Microcrystalline cellulose | 95g |
| Sodium carboxymethyl starch | 10g |
Preparation process：
After oleic acid LABRAFIL M 1944CS, ethyl oleate mixing, dronedarone hydrochloride is added thereto and is stirred to dissolve, then according to
Secondary addition Tween-80, propylene glycol, stirring make it after mixing, add in microcrystalline cellulose, sodium carboxymethyl starch, mixing, with water
Pellet is prepared using centrifugal granulation for adhesive, it is encapsulated to obtain the final product.
Embodiment 9：The preparation of dronedarone hydrochloride Solid Self-microemulsion micro pill capsule
| Dronedarone hydrochloride | 3g |
| Diethylene glycol monoethyl ether | 70g |
| Caprylic capric glyceryl ester | 5g |
| Solutol HS15 | 5g |
| Emulsifier EL-35 | 5g |
| Microcrystalline cellulose | 95g |
| Sodium carboxymethyl starch | 10g |
Preparation process：
Dronedarone hydrochloride is added in diethylene glycol monoethyl ether and is stirred to dissolve, sequentially adds caprylic capric triglycerin
Ester, Solutol HS15, Emulsifier EL-35, stirring make it after mixing, add in microcrystalline cellulose
Element, sodium carboxymethyl starch, mixing, extrusion spheronization method prepare pellet, it is encapsulated to obtain the final product.
Claims (6)
1. a kind of dronedarone hydrochloride self-micro emulsion formulation, it is characterised in that：The dronedarone hydrochloride self-micro emulsion formulation is liquid
Self-micro emulsion formulation is made of dronedarone hydrochloride, oil phase, emulsifier, assistant for emulsifying agent.
2. a kind of dronedarone hydrochloride self-micro emulsion formulation, it is characterised in that：The dronedarone hydrochloride self-micro emulsion formulation is solid
Self-micro emulsion formulation, after forming liquid self-micro emulsion formulation by dronedarone hydrochloride, oil phase, emulsifier, assistant for emulsifying agent, then into one
Step is made with excipient.
3. dronedarone hydrochloride self-micro emulsion formulation according to claim 1 or claim 2, it is characterised in that：Liquid self-micro emulsion formulation institute
It is with each raw material percentage：Dronedarone hydrochloride 1% ~ 10%, oil phase 5% ~ 80%, emulsifier 5% ~ 60%, assistant for emulsifying agent
5% ~ 60%, the sum of each raw material weight percentage is 100%；
Wherein, the oil phase is Sunsoft 8090, oleic acid LABRAFIL M 1944CS, ethyl oleate, caprylic capric triglycerin
One or more of ester, oleic acid；
The emulsifier is Labraso, Tween-80, Solutol HS15, polyoxy second
One or more of 35 castor oil of alkene, -40 rilanit special of polyethylene glycol；
The assistant for emulsifying agent is one or more of diethylene glycol monoethyl ether, propylene glycol, polyethylene glycol 400, glycerine.
4. dronedarone hydrochloride self-micro emulsion formulation according to claim 2, it is characterised in that：Liquid self-micro emulsion formulation and figuration
The weight ratio of agent is 1:1~1:60；
The excipient is one or more of microcrystalline cellulose, lactose, PVP K30, silica.
5. a kind of preparation method of dronedarone hydrochloride self-micro emulsion formulation as described in claim 1, it is characterised in that：Hydrochloric acid is determined
How Dalong is added in oil phase, emulsifier or assistant for emulsifying agent after dissolving, is added other raw materials and is uniformly mixed, filling in soft capsule
In to obtain the final product.
6. a kind of preparation method of dronedarone hydrochloride self-micro emulsion formulation as claimed in claim 2, it is characterised in that：Hydrochloric acid is determined
How Dalong is added in oil phase, emulsifier or assistant for emulsifying agent after dissolving, and addition prepares other originals needed for liquid self-micro emulsion formulation
Material is uniformly mixed, then liquid self-micro emulsion formulation obtained is uniformly mixed with excipient, is prepared into using direct powder compression
Tablet；Or dry granulation or wet granulation technology are used, it is mixed with other auxiliary materials, tabletting prepares piece agent；Or by squeezing
Go out spheronization, centrifugal granulation is prepared into pellet, be fitted into hard shell capsules；
Other described auxiliary materials include disintegrant, adhesive, lubricant.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711378959.9A CN108042489A (en) | 2017-12-19 | 2017-12-19 | A kind of dronedarone hydrochloride self-micro emulsion formulation and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711378959.9A CN108042489A (en) | 2017-12-19 | 2017-12-19 | A kind of dronedarone hydrochloride self-micro emulsion formulation and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108042489A true CN108042489A (en) | 2018-05-18 |
Family
ID=62130080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711378959.9A Pending CN108042489A (en) | 2017-12-19 | 2017-12-19 | A kind of dronedarone hydrochloride self-micro emulsion formulation and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108042489A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101152154A (en) * | 2006-09-29 | 2008-04-02 | 北京德众万全药物技术开发有限公司 | Hydrochloric acid dronedarone medicinal compositions for oral use and method for preparing the same |
| CN102349889A (en) * | 2011-11-01 | 2012-02-15 | 江苏先声药物研究有限公司 | Composition containing dronedarone |
| US20130116316A1 (en) * | 1997-06-23 | 2013-05-09 | Sanofi | Solid Pharmaceutical Compositions Containing Benzofuran Derivatives |
| CN103126994A (en) * | 2011-12-05 | 2013-06-05 | 北京虹湾医药技术有限公司 | Solid medicine composition containing dronedarone |
| CN104771375A (en) * | 2014-01-15 | 2015-07-15 | 山东新时代药业有限公司 | Dronedarone hydrochloride tablet and preparation method thereof |
| CN105640886A (en) * | 2016-03-17 | 2016-06-08 | 中国人民解放军南京军区福州总医院 | Sirolimus self-microemulsion preparation and preparation method thereof |
-
2017
- 2017-12-19 CN CN201711378959.9A patent/CN108042489A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130116316A1 (en) * | 1997-06-23 | 2013-05-09 | Sanofi | Solid Pharmaceutical Compositions Containing Benzofuran Derivatives |
| CN101152154A (en) * | 2006-09-29 | 2008-04-02 | 北京德众万全药物技术开发有限公司 | Hydrochloric acid dronedarone medicinal compositions for oral use and method for preparing the same |
| CN102349889A (en) * | 2011-11-01 | 2012-02-15 | 江苏先声药物研究有限公司 | Composition containing dronedarone |
| CN103126994A (en) * | 2011-12-05 | 2013-06-05 | 北京虹湾医药技术有限公司 | Solid medicine composition containing dronedarone |
| CN104771375A (en) * | 2014-01-15 | 2015-07-15 | 山东新时代药业有限公司 | Dronedarone hydrochloride tablet and preparation method thereof |
| CN105640886A (en) * | 2016-03-17 | 2016-06-08 | 中国人民解放军南京军区福州总医院 | Sirolimus self-microemulsion preparation and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105395492B (en) | A kind of volatile oil solid self-emulsifying tablet and preparation method thereof | |
| CN105617133B (en) | Composite peony seed oil self-emulsifying system composition and preparation method thereof | |
| CN101961306B (en) | Preparation method of low melting point drug solid dispersion | |
| CN102470121B (en) | Pharmaceutical compositions comprising dronedarone | |
| CN108042489A (en) | A kind of dronedarone hydrochloride self-micro emulsion formulation and preparation method thereof | |
| CN107669645A (en) | The preparation method of ciprofloxacin hydrocloride tablets | |
| CN114225042B (en) | Indobufen-containing pharmaceutical composition and preparation method thereof | |
| WO2016124966A1 (en) | Inclusion complex between cyclodextrin and non-ionic surfactants | |
| CN106309395A (en) | Tacrolimus sustained-release tablets and preparation method thereof | |
| JP2007161588A (en) | Solid dispersion of fenofibrate and therapeutic agent for hyperlipemia containing the dispersion | |
| CN107126420A (en) | A kind of high-dissolution fenofibrate and preparation method thereof | |
| CN100427084C (en) | Oral silybin sustained release agent and preparation thereof | |
| CN102302470B (en) | Nitrendipine soft capsule | |
| CN101744785A (en) | Quick-release tablet and preparation method thereof | |
| CN102204879A (en) | Preparation method of ginkgolide B solid dispersion | |
| CN106692106A (en) | Fycompa self-microemulsion preparation and preparation method thereof | |
| CN102552292A (en) | Alendronate vitamin D3 pharmaceutical preparation | |
| CN107441055A (en) | A kind of preparation method of controlled release drug | |
| US20090326078A1 (en) | Process for preparing a solid dosage form | |
| CN106619513A (en) | Safinamide self-microemulsion preparation and preparation method thereof | |
| CN102120004A (en) | Method for preparing heart calming and mind tranquilizing preparation | |
| CN102091044B (en) | Cefuroxime axetil lipid microsphere solid preparation | |
| CRISAN et al. | PRE-FORMULATION, FORMULATION AND PILOT SCALE-UP STUDIES TO ESTABLISH THE QUALITATIVE AND QUANTITATIVE COMPOSITION OF AN INNOVATIVE NANOFORM DIETARY SUPPLEMENT FOR MENOPAUSAL THERAPY. | |
| CN102552595A (en) | Siqitang integrated novel dosage form and production method thereof | |
| CN107982216A (en) | A kind of pomalidomide self-micro emulsion formulation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180518 |